Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Science 2014 Dec 13;346(6216):1480-6. Epub 2014 Nov 13.

Massachusetts General Hospital Cancer Center, Department of Medicine and Harvard Medical School, Boston, MA 02114, USA.

Targeted cancer therapies have produced substantial clinical responses, but most tumors develop resistance to these drugs. Here, we describe a pharmacogenomic platform that facilitates rapid discovery of drug combinations that can overcome resistance. We established cell culture models derived from biopsy samples of lung cancer patients whose disease had progressed while on treatment with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors and then subjected these cells to genetic analyses and a pharmacological screen. Multiple effective drug combinations were identified. For example, the combination of ALK and MAPK kinase (MEK) inhibitors was active in an ALK-positive resistant tumor that had developed a MAP2K1 activating mutation, and the combination of EGFR and fibroblast growth factor receptor (FGFR) inhibitors was active in an EGFR mutant resistant cancer with a mutation in FGFR3. Combined ALK and SRC (pp60c-src) inhibition was effective in several ALK-driven patient-derived models, a result not predicted by genetic analysis alone. With further refinements, this strategy could help direct therapeutic choices for individual patients.

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.1254721DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388482PMC
December 2014
103 Reads
31.480 Impact Factor

Publication Analysis

Top Keywords

drug combinations
12
inhibitors active
8
effective drug
8
growth factor
8
factor receptor
8
patient-derived models
8
combination alk
4
alk mapk
4
example combination
4
screen multiple
4
multiple effective
4
identified example
4
combinations identified
4
kinase mek
4
resistant tumor
4
tumor developed
4
alk-positive resistant
4
active alk-positive
4
pharmacological screen
4
mek inhibitors
4

References

(Supplied by CrossRef)

Similar Publications